Prevention of Venous Thromboembolism in Hospitalized Medical Patients

REFERENCES

• Goldhaber S. Pulmonary embolism. New Engl J Med 1998; 339(2)93–104
   PubMed Web of Science ®Google Scholar
• Geerts W. H., Bergqvist D., Pineo G. F., Heit J. A., Samama C. M., Lassen M. R., et al. Prevention of venous thromboembolism: ACCP evidence-based clinical practice guidelines (8th edition). Chest 2008; 133(Suppl. 6)381S–453S
   PubMedGoogle Scholar
• Heit J. A. Venous thromboembolism epidemiology: implications for prevention and management. Sem Thromb Hemost 2002; 28(Suppl. 2)3–13
   PubMedGoogle Scholar
• Alpert J. S., Dalen J. E. Epidemiology and natural history of venous thromboembolism. Prog Cardiovasc Dis 1994; 36(6)417–422
   PubMed Web of Science ®Google Scholar
• White R. H. The epidemiology of venous thromboembolism. Circulation 2003; 107(Suppl. 1)14–18
   Google Scholar
• White R. H., Zhou H., Romano P. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Int Med 1998; 128(9)737–740
   PubMed Web of Science ®Google Scholar
• Jimenez D., Diaz G., Marin E., Vidal R., Sueiro A., Yusen R. D. The risk of recurrent venous thromboembolism in patients with unprovoked symptomatic deep vein thrombosis and asymptomatic pulmonary embolism. Thromb Haemost 2006; 95(3)562–566
   PubMed Web of Science ®Google Scholar
• Heit J. A. The epidemiology of venous thromboembolism in the community. Arterioscler, Thromb, Vasc Biol 2008; 28(3)370–372
   PubMed Web of Science ®Google Scholar
• Schulman S., Lindmarker P., Holmstrom M., Larfars S., Carlsson A., Nicol P., et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost 2006; 4(4)734–742
   PubMed Web of Science ®Google Scholar
• Cohen A. T., Tapson V. F., Bergmann J. F., Goldhaber S. Z., Kakkar A., Deslandes B., et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE investigators study): a multinational cross-sectional study. Lancet 2008; 371(9610)387–394
   PubMed Web of Science ®Google Scholar
• Piazza G., Seddighzadeh A., Goldhaber S. Z. Double trouble for 2,609 hospitalized medical patients who developed deep vein thrombosis: prophylaxis omitted more often and pulmonary embolism more frequent. Chest 2007; 132(2)554–561
   PubMed Web of Science ®Google Scholar
• Samama M. M., Cohen A. T., Darmon J. Y., Desjardins L., Eldor A., Janbon C., et al. Comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in medical patients with Enoxaparin Study Group. N Engl J Med 1999; 341(11)793–800
   PubMed Web of Science ®Google Scholar
• Alikhan R., Peters F., Wilmott R., Cohen A. T. Fatal pulmonary embolism in hospitalized patients: a necropsy review. J Clin Pathol 2004; 57(12)1254–1257
   PubMed Web of Science ®Google Scholar
• Lyman G. H., Khorana A. A., Falanga A., Clarke-Pearson D., Flowers C., Jahanzeb M., et al. American Society of Clinical Oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25(34)5490–5505
   PubMed Web of Science ®Google Scholar
• Stain M., Schönauer V., Minar E., Bialonczyk C., Hirschl M., Weltermann A., et al. The post-thrombotic syndrome: risk factors and impact on the course of thrombotic disease. J Thromb Haemost 2005; 3(12)2671–2676
   PubMed Web of Science ®Google Scholar
• Pengo V., Lensing A. W. A., Prins M. H., Marchiori A., Davidson B. L., Tiozzo F., et al. Thromboembolic Pulmonary Hypertension Study Group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004; 350(22)2257–2264
   PubMed Web of Science ®Google Scholar
• Dimick J. B., Chen S. L., Taheri P. A., Henderson W. G., Khuri S. F., Campbell D. A., Jr. Hospital costs associated with surgical complications: a report from the private-sector national surgical quality improvement program. J Am Coll Surg 2004; 199(4)531–537
   PubMed Web of Science ®Google Scholar
• Anderson F. A., Jr., Zayaruzny M., Heit J. A., Fidan D., Cohen A. T. Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol 2007; 82(9)777–782
   PubMed Web of Science ®Google Scholar
• Menajovsky L. B., Spandorfer J. Benefits of more aggressive VTE prophylaxis in hospitalized medical patients. Cleve Clin J Med 2004; 71(12)747–760
   Google Scholar
• Caprini J. A. Thrombosis risk assessment as a guide to quality patient care. Dis Mon 2005; 51(2-3)70–78
   PubMed Web of Science ®Google Scholar
• Alikhan R., Cohen A. T., Combe S., Samama M. M., Desjardins L., Eldor A., et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness. Analysis of the MEDENOX study. Arch Intern Med 2004; 164(9)963–968
   PubMed Web of Science ®Google Scholar
• Leizorovicz A., Cohen A. T., Turpie A. G., Olsson C. G., Vaitkus P. T., Goldhaber S. Z., et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110(7)874–879
   PubMed Web of Science ®Google Scholar
• Cohen A. T., Davidson B. L., Gallus A. S., Lassen M. R., Prins M. H., Tomkowski W., et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006; 332(7537)325–329
   PubMed Web of Science ®Google Scholar
• Kleber F. X., Witt C., Vogel G., Koppenhagen K., Schomaker U., Flosbach C. W. The-PRINCE Study Group: randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 2003; 145(4)614–621
   PubMed Web of Science ®Google Scholar
• Alikhan R., Cohen A. T., Combe S., Samama M. M., Desjardins L., Eldor A., et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coag Fibrinolysis 2003; 14(4)341–346
   PubMed Web of Science ®Google Scholar
• Cohen A. T., Turpie A. G., Leizorovicz A., Olsson C. G., Vaitkus P. T., Goldhaber S. Z. Thromboprophylaxis with dalteparin in medical patients: which patients benefit?. Vasc Med 2007; 12(2)123–127
   PubMed Web of Science ®Google Scholar
• Eichenger S., Hron G., Bialonczyk C., Hirschl M., Minar E., Wagner O., et al. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med 2008; 168(15)1678–1683
   PubMed Web of Science ®Google Scholar
• Dentali F., Douketis J. D., Gianni M., Lim W., Crowther M. A. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 2007; 146(4)278–288
   PubMed Web of Science ®Google Scholar
• Making Health Care Safer: A Critical Analysis of Patient Safety Practices, K. G. Shojania, B. W. Duncan, K. M. McDonald, R. M. Wachter. Agency for Healthcare Research and Quality, Rockville, MD 2001, Accessed at www.ahrq.gov/clinic/ptsafety/ Evidence Report/Technology Assessment no. 43. AHRQ publication 01-E058 on October 8, 2006
   Google Scholar
• The Surgeon General's Call to Action to Prevent Venous Thrombosis and Pulmonary Embolism. Office of the Surgeon General, Rockville, MD 2008, Accessed at www.surgeongeneral.gov/topics/deepvein/calltoaction/call-to-action-on-dvt-2008.pdf on September 16, 2008
   Google Scholar
• King C. S., Holley A. B., Jackson J. L., Shorr A. F., Moores L. K. Twice vs. three times daily heparin dosing for thromboembolism prophylaxis in the general medical population: a metaanalysis. Chest 2007; 131(2)507–516
   PubMed Web of Science ®Google Scholar
• Mismetti P., Quenet S., Levine M., Merli G., Decousus H., Derobert E., et al. Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism. An individual patient data meta-anlaysis. Chest 2005; 128(4)2203–2210
   PubMed Web of Science ®Google Scholar
• Kanaan A. O., Silva M. A., Donovan J. L., Roy T., Al-Homsi A. S. Meta-analysis of venous thromboembolism prophylaxis in medically ill patients. Clin Ther 2007; 29(11)2395–2405
   PubMed Web of Science ®Google Scholar
• Tapson V. F., Decousus H., Pini M., Chong B. H., Froehlich J. B., Monreal M., et al. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest. 2007; 132(3)936–945
   PubMed Web of Science ®Google Scholar
• Burleigh E., Wang C., Foster D., Heller S., Dunn D., Safavi K., et al. Thromboprophylaxis in medically ill patients at risk for venous thromboembolism. Am J Health Syst Pharm 2006; 63(20 Suppl. 6)S23–S29
   PubMedGoogle Scholar
• Creekmore F. M., Oderda G. M., Pendleton R. C., Brixner D. I. Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism. Pharmacotherapy 2006; 26(10)1438–1445
   PubMed Web of Science ®Google Scholar
• Shorr A. F., Jackson W. L., Weiss B. M., Moores L. K. Low-molecular weight heparin for deep vein thrombosis prophylaxis in hospitalized medical patients: results from a cost-effectiveness analysis. Blood Coagul Fibrinolysis 2007; 18(4)309–316
   PubMed Web of Science ®Google Scholar
• Schädlich P. K., Kentsch M., Weber M., Kämmerer W., Brecht J. G., Nadipelli V., et al. Cost effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients: modelling study from the hospital perspective in Germany. Pharmacoeconomics 2006; 24(6)571–591
   PubMed Web of Science ®Google Scholar
• Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy—III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 1994; 308(6923)235–246
   PubMed Web of Science ®Google Scholar
• Antiplatelet Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002; 324(7329)71–86
   PubMed Web of Science ®Google Scholar
• Glynn R. J., Ridker P. M., Goldhaber S. Z., Burning J. E. Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial. Ann Intern Med 2007; 147(8)525–533
   PubMed Web of Science ®Google Scholar
• Glynn R. J., Ridker P. M., Goldhaber S. Z., Zee R. Y., Burning J. E. Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the women's health study. Circulation 2007; 116(13)1497–1503
   PubMed Web of Science ®Google Scholar
• Stein P. D., Kayali F., Olson R. R. Twenty-one-year trends in the use of inferior vena cava filters. Arch Intern Med 2004; 164(14)1541–1545
   PubMed Web of Science ®Google Scholar
• Kaufman J. A., Kinney T. B., Streiff M. B., Sing R. F., Proctor M. C., Becker D., et al. Guidelines for the use of retrievable and convertible vena cava filters: report from the Society of Interventional Radiology Multidisciplinary Consensus Conference. J Vasc Interv Radiol 2006; 17(3)449–459
   PubMed Web of Science ®Google Scholar
• Tapson V. F. Acute pulmonary embolism. N Engl J Med 2008; 358(10)1037–1052
   PubMed Web of Science ®Google Scholar
• Khorana A. A. The NCCN clinical practice guidelines on venous thromboembolic disease: strategies for improving VTE prophylaxis in hospitalized cancer patients. Oncologist 2007; 12(11)1351–1370
   PubMedGoogle Scholar
• Spencer F. A., Lessard D., Emery C., Reed G., Goldberg R. J. Venous thromboembolism in the outpatient setting. Arch Intern Med 2007; 167(14)1471–1475
   PubMed Web of Science ®Google Scholar
• Hull R. D., Schellong S. M., Tapson V. F., Yusen R., Monreal M., Samama M. M., et al. Extended venous thromboembolism (VTE) prophylaxis in acutely ill medical patients with recent reduced mobility: the EXCLAIM study. Presented at International Society on Thrombosis and Haemostasis XXI Congress, GenevaSwitzerland, July, 6–122007, Abstract O-S-001
   Google Scholar
• Shrivastava S., Ridker P. M., Glynn R. J., Goldhaber S. Z., Moll S., Bounameaux H., et al. D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Throm Haemost 2006; 4(6)1208–1214
   PubMed Web of Science ®Google Scholar
• Kakkar A. K., Levine M., Pinedo H. M., Wolff R., Wong J. Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist 2003; 8(4)381–388
   PubMed Web of Science ®Google Scholar
• Kucher N., Koo S., Quiroz R., Cooper J. M., Paterno M. D., Soukonnikov B., et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med 2005; 352(10)969–977
   PubMed Web of Science ®Google Scholar
• Gerber D. E., Grossman S. A., Streiff M. B. Management of venous thromboembolism in patients with primary and metastatic brain tumors. J Clin Oncol 2006; 24(8)1310–1318
   PubMed Web of Science ®Google Scholar
• Goldhaber S. Z., Dunn K., Gerhard-Herman M., Park J. K., Black P. M. Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. Chest 2002; 122(6)1933–1937
   PubMed Web of Science ®Google Scholar
• Falgá C., Capdevila J. A., Soler S., Rabuñal R., Sánchez Muñoz-Torrero J. F., Gallego P., et al. Clinical outcome of patients with venous thromboembolism and renal insufficiency. Findings from the RIETE registry. Thromb Haemost 2007; 98(4)771–776
   PubMed Web of Science ®Google Scholar